Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeEXECUTIVESJay M. Moyes Appointed New CFO of Sera Prognostics

Jay M. Moyes Appointed New CFO of Sera Prognostics

Mr. Moyes joins Sera Prognostics as it transitions from rigorous scientific and groundbreaking clinical-stage company into a rapidly growing commercial organization.

For more than two decades, Jay Moyes has served in C-level executive and board positions of both private and public companies. He currently serves as Director on the public boards of Achieve Life Sciences (NASDAQ: ACHV), BioCardia (NASDAQ: BCDA) and Puma Biotechnologies (NASDAQ: PBYI). Previous roles include board director service with Predictive Technology Group (PRED); Osiris Therapeutics (OSIR); and Integrated Diagnostics (acquired by Biodesix). Jay also served as Chief Financial Officer and Director of the publicly traded biomaterials company, Amedica Corporation (now SINTX Technologies), managing the company’s IPO and listing on NASDAQ; and as Chief Financial Officer at XDx (now CareDx – CDNA).

At Myriad Genetics (MYGN) , Jay led the finance function for 14 years from the company’s early private stage development beginning with 7 employees, through its successful IPO in 1996, and serving until 2007 as Chief Financial Officer during Myriad’s rapid growth trajectory to become one of the world’s most highly profitable molecular diagnostics companies, with over 900 employees.  During that time, Moyes spearheaded the efforts in raising more than $500 million in public and private financings.

“I am thrilled to be working with Jay Moyes again, as we build Sera Prognostics into a highly successful and profitable enterprise,” said Gregory C. Critchfield, MD., MS, chairman and CEO. “Jay’s deep financing connections and expertise in leading biopharmaceutical, medical device and diagnostics companies, both in private and public company settings, will help Sera to achieve its vision of improving the health of mothers and babies and reducing the costs of healthcare delivery.”

Sera has achieved remarkable progress in building a world-class approach to address the immense burden of premature birth,” said Jay Moyes.  “The early data from outcome study reports show that Sera’s PreTRM® strategy works, and that by improving the health of women and babies, the enormous personal, societal and economic consequences of prematurity can be mitigated.  I am excited to join the talented Sera team and help accelerate the company’s progress, as Greg and I successfully did together at Myriad.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy